Gilead Sciences (GILD) Aktienübersicht
Das biopharmazeutische Unternehmen Gilead Sciences, Inc. erforscht, entwickelt und vermarktet Medikamente in Bereichen mit ungedecktem medizinischem Bedarf in den Vereinigten Staaten, Europa und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 5/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 5/6 |
GILD Community Fair Values
Create NarrativeSee what 214 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
LO
Fair Value from
US$7.675.4% unterbewertet intrinsischer Abschlag
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeGilead Sciences, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$134.06 |
| 52-Wochen-Hoch | US$157.29 |
| 52-Wochen-Tief | US$95.30 |
| Beta | 0.33 |
| 1 Monat Veränderung | -3.42% |
| 3 Monate Veränderung | -12.09% |
| 1 Jahr Veränderung | 36.57% |
| 3 Jahre Veränderung | 70.34% |
| 5 Jahre Veränderung | 94.54% |
| Veränderung seit IPO | 21,084.81% |
Aktuelle Nachrichten und Updates
Recent updates
Analyse-Update • May 01
GILD: Future Returns Will Hinge On Executing Oncology And ADC Acquisitions
Analysts have raised the Gilead Sciences fair value estimate by about $2 to $128.42 per share, supported by refreshed models that reflect updated revenue growth, profitability, and future P/E assumptions following a wave of higher Street price targets. Analyst Commentary Street research on Gilead has tilted constructive in recent weeks, with several firms lifting price targets and at least one new Buy rating added.Seeking Alpha • Apr 20
Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't
Summary Gilead Sciences, Inc. remains heavily reliant on its dominant HIV division, which drives recent share price growth and provides stability through 2036 patent protection. Despite a recent $11bn M&A spree targeting oncology and immunology, GILD faces skepticism due to a poor track record and lack of near-term revenue from new acquisitions. I expect Q1 earnings to be somewhat underwhelming, with sluggish growth and minor IPR&D charges, but GILD trades at a below-average forward P/E of ~16x versus peers. I continue to hold GILD for its robust HIV franchise and >2% dividend yield, while awaiting evidence that management can successfully execute on oncology ambitions. Read the full article on Seeking Alpha
Analyse-Update • Apr 17
GILD: Oncology Deals And HIV Franchise Will Support Future Earnings
Analysts have raised the price target for Gilead Sciences to $180, citing recent upward revisions across Wall Street that reflect updated views on revenue growth, profitability and oncology deal activity. The core fair value estimate in this framework also remains at $180.Analyse-Update • Apr 03
GILD: HIV And PrEP Franchise Will Support Future Earnings And Margin Strength
Analysts have lifted the fair value estimate for Gilead Sciences to $180 from $159, citing higher modeled revenue growth, a slightly lower discount rate, and support from a wave of recent price target raises and positive initiation commentary on the company’s positioning and operating margins. Analyst Commentary Street research around Gilead Sciences has been active, with several bullish analysts updating their views and price targets in recent weeks.
Analyse-Update • Mar 20
GILD: HIV Franchise And Oncology Expansion Will Shape Bullish Long Term Outlook
The analyst fair value estimate for Gilead Sciences has moved from $132.57 to $157.43, with analysts pointing to stronger modeled revenue growth, slightly higher long term profit margins, and a higher future P/E multiple supported by recent price target hikes and positive views on the company's positioning in large cap biotech. Analyst Commentary Recent Street research on Gilead Sciences reflects a mix of optimism around growth drivers and caution around valuation and competitive risks.Analyse-Update • Mar 05
GILD: Rich HIV Outlook Will Depend On Delivering High-Risk Oncology Acquisitions
Analysts have lifted their Gilead Sciences fair value estimate from $122.64 to $126.09 as they update models to reflect revised revenue growth and profit margin assumptions, along with a slightly higher discount rate and a modestly lower future P/E multiple, following a wave of higher Street price targets in recent weeks. Analyst Commentary Recent Street research around Gilead Sciences shows a mix of optimism and restraint.Analyse-Update • Feb 19
GILD: Elevated Future Expectations Will Hinge On Execution In Oncology
Gilead Sciences' updated analyst price target has moved sharply higher to $122.64 from $91.83, as analysts broadly lift their targets into the $140 to $170 range, citing steadier HIV franchise expectations, contributions from recent launches, and adjusted assumptions for expenses and oncology assets. Analyst Commentary Recent Street research shows a clear tilt toward higher valuation frameworks for Gilead Sciences, with several firms taking their targets into a broad US$140 to US$170 range.Analyse-Update • Feb 05
GILD: Extended HIV And PrEP Strength Will Support Steady Long-Term Earnings Power
Narrative Update: Gilead Sciences Analyst Price Target Shift Analysts have lifted their price targets on Gilead Sciences by as much as US$20, pointing to updated HIV franchise expectations, revised oncology and PrEP assumptions, and refreshed valuation approaches, even as some models incorporate higher IPR&D expenses and adjusted sales forecasts. Analyst Commentary Recent Street research around Gilead centers on two big themes in the models: the durability of the HIV franchise and the ramp in newer areas like PrEP and oncology, with several bullish analysts lifting price targets and reaffirming positive ratings.Analyse-Update • Jan 22
GILD: Extended HIV Franchise Strength Will Support Stronger Long-Term Earnings Power
Analysts have nudged their fair value estimate for Gilead Sciences up to $159 from $153, citing refreshed models that reflect updated HIV franchise expectations, oncology pipeline inputs, and evolving competitive readthroughs from peers in hepatitis and cell therapy. Analyst Commentary Recent Street research around Gilead Sciences has leaned constructive, with several bullish analysts refining their models and resetting price targets while pointing to HIV, oncology, and select liver and autoimmune assets as the key drivers they are watching.Analyse-Update • Jan 07
GILD: HIV PrEP Strength And Oncology Mixed Results Will Shape Outlook
Analysts have nudged their price targets on Gilead Sciences higher, generally toward the US$140 to US$145 range. They cite expectations for stronger HIV PrEP contributions from Yeztugo, a healthier outlook for the broader HIV portfolio including Biktarvy, and ongoing support from oncology and newer launches such as Livdelzi.Analyse-Update • Dec 20
GILD: Extended HIV Exclusivity Will Support Stronger Long-Term Earnings Power
Analysts have raised their fair value estimate for Gilead Sciences to $153 from $140, citing extended Biktarvy exclusivity, a stronger long term HIV growth outlook supported by Yeztugo and PrEP, and increasing conviction in oncology and broader large cap biopharma innovation potential. Analyst Commentary Bullish analysts continue to highlight Gilead as a core large cap biopharma holding, pointing to a healthier long term growth profile in HIV and a strengthening contribution from oncology.Analyse-Update • Dec 06
GILD: Extended HIV Franchise Will Offset Oncology And Policy Uncertainty Ahead
Analysts have nudged their blended price target for Gilead Sciences slightly lower by about $0.20 to the low-$130s, reflecting modestly higher discount rates and more conservative HIV and oncology growth and margin assumptions, even as they highlight extended Biktarvy exclusivity, encouraging Yeztugo uptake, and anito cel driven oncology optionality as key long term value drivers. Analyst Commentary Bullish analysts largely frame the recent price target tweaks as fine tuning within an increasingly constructive long term view, pointing to extended HIV cash flows, a strengthening PrEP opportunity, and optionality in oncology despite early stage competitive readouts.Analyse-Update • Nov 22
GILD: Extended Exclusivity And PrEP Opportunities Will Balance Ongoing Oncology And Policy Pressures
Analysts have modestly raised their price target for Gilead Sciences to $130.83 per share from $129.51. They cite the extended exclusivity period for Biktarvy and improved growth prospects in the HIV market as key drivers for the upward revision.Analyse-Update • Nov 08
GILD: HIV Business Strength And Patent Extension Will Balance Oncology Risks Ahead
Gilead Sciences' price target has been raised by analysts from $127 to $145. This reflects confidence in stable HIV business trends and improved execution, which offsets ongoing oncology and cell therapy challenges.Analyse-Update • Oct 25
Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies
Gilead Sciences' analyst price target has increased from $126 to $127 per share. Analysts point to continued strong uptake of the Yeztugo launch in HIV and the recent Biktarvy patent extension as supporting factors, despite some pipeline setbacks.Analyse-Update • Oct 10
Global Healthcare Trends Will Expand Access To Advanced Therapies
Gilead Sciences saw its analyst price target increase from $124.91 to $126.31. Analysts cited improved sales forecasts for key HIV treatments and enhanced revenue growth expectations as the primary drivers of the upward revision.Analyse-Update • Sep 04
Global Healthcare Trends Will Expand Access To Advanced Therapies
Analysts remain constructive on Gilead Sciences, citing strong HIV franchise performance, positive FDA developments, and favorable regulatory tailwinds offsetting minor pipeline setbacks, resulting in an unchanged consensus price target of $124.37. Analyst Commentary Yeztugo’s FDA approval and clean label, strong clinical data, and convenient twice-yearly dosing are seen as key drivers for Gilead’s HIV franchise growth, with analysts generally positive on long-term adoption despite initial ramp expectations being slow and some cannibalization of Descovy anticipated.Analyseartikel • Jul 27
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • May 15
Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are
Even though Gilead Sciences, Inc.'s ( NASDAQ:GILD ) recent earnings release was robust, the market didn't seem to...Seeking Alpha • Apr 25
Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance
Summary Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest performer, with Biktarvi leading the charge, while oncology investments have yet to yield significant returns. Key upcoming milestones include the FDA decision on lenacapavir, a potential blockbuster HIV therapy, and various oncology and cell therapy data readouts. Despite recent share price growth, I am downgrading GILD stock to "Hold" due to concerns over oncology and cell therapy prospects and limited upside potential. Read the full article on Seeking AlphaNeue Analyse • Apr 08
New HIV, Livdelzi And CAR T Options Will Expand Reach
Gilead's innovation in HIV and oncology treatments supports revenue growth and market expansion in these therapeutic areas.Seeking Alpha • Mar 16
Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally
Summary Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to overcome the flat HIV segment forecast. DCF modeling shows Gilead is priced for 0% growth, which aligns with near-term revenue expectations. Heavy reliance on HIV franchise (72% of revenue) creates vulnerability despite diversification efforts in oncology. Following a 57% rally since June, Gilead now trades at fair value relative to its modest growth outlook, meriting a rating downgrade to "hold" and "market perform." Read the full article on Seeking AlphaAktionärsrenditen
| GILD | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 2.5% | 1.2% | 2.1% |
| 1Y | 36.6% | 41.9% | 30.6% |
Rendite im Vergleich zur Industrie: GILD unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 41.9% erzielte.
Rendite vs. Markt: GILD übertraf den Markt US, der im vergangenen Jahr eine Rendite von 30.6 erzielte.
Preisvolatilität
| GILD volatility | |
|---|---|
| GILD Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: GILD hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: GILDDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1987 | 17,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc. ist ein biopharmazeutisches Unternehmen, das Medikamente in Bereichen mit ungedecktem medizinischem Bedarf in den Vereinigten Staaten, Europa und international erforscht, entwickelt und vermarktet. Das Unternehmen bietet Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza und Yeztugo für die Behandlung von HIV-1-Infektionen bei Patienten. Es bietet auch Epclusa, Livdelzi und Vemlidy zur Behandlung von chronischer Hepatitis C, primärer biliärer Cholangitis und chronischer Hepatitis B; Tecartus, eine T-Zell-Therapie zur Behandlung erwachsener Patienten; Trodelvy, eine Injektion zur intravenösen Anwendung; und Yescarta, eine Suspension zur intravenösen Infusion, ist eine CAR-T-Zell-Therapie zur Behandlung erwachsener Patienten.
Gilead Sciences, Inc.'s Grundlagenzusammenfassung
| GILD grundlegende Statistiken | |
|---|---|
| Marktanteil | US$169.18b |
| Gewinn(TTM) | US$8.51b |
| Umsatz(TTM) | US$29.44b |
19.6x
Kurs-Gewinn-Verhältnis 5.7x
Kurs-Umsatz-VerhältnisIst GILD zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| GILD Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$29.44b |
| Kosten der Einnahmen | US$6.23b |
| Bruttogewinn | US$23.21b |
| Sonstige Ausgaben | US$14.70b |
| Gewinn | US$8.51b |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 6.86 |
| Bruttomarge | 78.84% |
| Nettogewinnspanne | 28.90% |
| Schulden/Eigenkapital-Verhältnis | 110.2% |
Wie hat sich GILD auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
2.4%
Aktuelle Dividendenrendite46%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/07 14:55 |
| Aktienkurs zum Tagesende | 2026/05/07 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Gilead Sciences, Inc. wird von 66 Analysten beobachtet. 27 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |